Quick Links
Head Office
Profound Medical Corp.,
2400 Skymark Avenue,
Unit #6, Mississauga, ON L4W 5K5, Canada
T: 647.476.1350
F: 647.847.3739
info@profoundmedical.com
AUA 2025
Las Vegas, Nevada
April 26 – 29
Join us live at AUA to learn more about TULSA-PRO. Visit us at booth #654, attend our educational events, or contact us for more information.
AUA Speaker Schedule
Saturday April 26
9:30AM-11:30AM
MP04-02: MRI-Guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: Single Institution Experience of Treatment Efficacy
Speaker: Dr. Jonathan Balcazar, UT Southwestern Medical Center
Type: Moderate Poster Session
Room: Casanova 503
MP06-19: Deep learning prostate segmentation module to assist in MRI-guided transurethral ultrasound (TULSA) treatment planning: validation study and real-world performance
Speaker: Dr. Mark Hong
Type: Moderate Poster Session
Room: Marco Polo 703
Sunday April 27
3:30PM-5:30PM
PD19-01: Final, three-year oncological results of a randomized clinical trial FARP comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer
Speaker: Dr. Eduard Baco, Oslo University Hospital
Type: Podium
Time: 3:30PM-3:38PM
Room: Marco Polo 805
PD19-07: Real-world outcomes after MRI-guided transurethral ultrasound ablation of the prostate in a multicenter post-market registry
Speaker: Dr. Ram Pathak, Mayo Clinic Florida, on behalf of the CARE registry
Type: Podium
Time: 4:18PM-4:26PM
Room: Marco Polo 805
Monday April 28
1:00PM-3:00PM
Successfully recruited: CAPTAIN randomized controlled trial comparing the TULSA procedure against radical prostatectomy
Speaker: Dr. Xiaosong Meng, UT Southwestern Medical Center, on behalf of the CAPTAIN trial
Type: Late-Break Session
Time: 2:04PM-2:12PM
Room: Hall C, The Square, Learning Lab
CAUTION: TULSA-PRO® is approved for commercial sale in the USA (K191200) & EU (CE 2797). Rx only device.
For all other Regulatory jurisdictions, please contact us at info@profoundmedical.com for more information regarding the regulatory status of the device.